- Previous Close
367.94 - Open
0.00 - Bid --
- Ask --
- Day's Range
367.94 - 367.94 - 52 Week Range
357.35 - 367.94 - Volume
0 - Avg. Volume
25,100 - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
14.74 - EPS (TTM)
24.95 - Earnings Date Feb 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
www.gsk.com70,212
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: GSK1N.MX
View MorePerformance Overview: GSK1N.MX
Trailing total returns as of 1/2/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GSK1N.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GSK1N.MX
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
8.02%
Return on Assets (ttm)
7.24%
Return on Equity (ttm)
21.85%
Revenue (ttm)
31.31B
Net Income Avi to Common (ttm)
2.51B
Diluted EPS (ttm)
24.95
Balance Sheet and Cash Flow
Total Cash (mrq)
3.21B
Total Debt/Equity (mrq)
119.37%
Levered Free Cash Flow (ttm)
6.04B